Innovation for Antibiotics Development and Preservation
Antimicrobial Resistance (AMR) is a growing global health threat. WHO is currently developing a Global Action Plan for AMR (GAP-AMR) that will be discussed by the 68th World Health Assembly in May 2015. The plan aims to provide guidance on the development of a multi-sectoral comprehensive, coordinated and sustained approach to address AMR. One goal of the GAP-AMR is to establish a mechanism to promote the discovery and development of novel antibiotics that are safe, and effective and ensure that any new molecules are accessible, and rationally used to avoid the development of resistance. Market failures in the discovery and development of new antibiotics are well documented which underscore the need for innovate approaches and models to sustainably encourage research and development (R&D) in this area.
13 MAY 2014: WHO Technical Consultation on Innovative Models for New Antibiotics’ Development and Preservation
A one day “Technical Consultation on Innovative Models for New Antibiotics’ Development and Preservation” was held at WHO headquarters on 13 May 2014. The meeting brought together leading experts to present and discuss innovative models fostering discovery and development of new antibiotics as part of the tool-kit to address challenges related to antimicrobial resistance (AMR).
The meeting was held under “Chatham House” rules where comments are not attributed to individual speakers.
8-9 DECEMBER 2014: Joint WHO-DNDi meeting on “Fostering the development and rational use of new antibiotics: How a product development partnership could promote innovation and responsible access to new antibiotics”
As a follow up to the WHO Technical Consultation on Innovative Models for New Antibiotics’ Development and Preservation that took place on 13 May 2014, WHO and the Drugs for Neglected Diseases initiative (DNDi) jointly organized a two-day technical consultation on 8-9 December 2014 in Geneva on research and development of new antibiotics. Growing antibiotic resistance globally and the low level of investment in R&D on antibiotics is increasingly considered one of the biggest global health threats. The meeting explored the potential need for a product development partnership to promote innovation, responsible use of and access to new antibiotics.